[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Dongyang Liu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100508008","a-study-on-the-effect-of-bariatric-surgery-on-glucose-metabolism-in-chinese-obese-and-type-2-diabetes-patients-100508008",false,"NCT05894811","A Study on the Effect of Bariatric Surgery on Glucose Metabolism in Chinese Obese and Type 2 Diabetes Patients","Inclusion Criteria:\n\n* BMI ≥ 28 kg\u002Fm2, meeting the indications for surgical weight loss surgery (gastrectomy)\n* Normal glucose tolerance group: HbA1c ≤ 5.6%; ≥ 6 cases aged 24 years or above\n* IGT patients: 5.7% ≤ HbA1c ≤ 6.4%; ≥ 12 cases aged 24 years or above\n* T2DM patients: Subjects with HbA1c ≥ 6.4% or HbA1c well controlled by medication can be diagnosed as T2DM based on self-reported or fasting\u002Fpostprandial blood glucose diagnosis; ≥ 12 cases aged 24 years and above.\n* Between the ages of 16 and 65 (inclusive), with no less than one-third of either gender\n* The subjects understand the content of the informed consent form and voluntarily sign it, which allows them to maintain good communication with the researchers and comply with the requirements of the clinical trial\n\nExclusion Criteria:\n\n* Type I diabetes patients (autoimmune diabetes patients with T1DM antibody)\n* Suffering from special types of diabetes, including cortisolism, growth hormone tumor, glucagon tumor and diabetes caused by some genetic factors\n* Significant weight loss occurred before enrollment (\\>3% weight loss in the first 3 months)\n* Participated in other research projects as a subject within 6 months prior to screening\n* Donate or lose ≥ 400 mL of blood within 8 weeks prior to screening\n* Regular use (cumulative use for 3 months in the past 12 months) or treatment with corticosteroids, contraceptives, thiazide diuretics, and quinolone antibiotics in the past two months\n* Regular use (cumulative use for 3 months in the past 12 months) or treatment with anti obesity drugs in the past two months\n* The following hypoglycemic drugs have been used routinely (for 3 months accumulatively in the past 12 months) or in the past two months: sulfonylureas (glibenclamide, glipizide, gliclazide, gliquidone, glimepiride, etc.), non sulfonylureas (repaglinide, nateglinide, migglinide, etc.), GLP-1 receptor agonists (exenatide, lilalutide, etc.) DPP-4 inhibitors (sigliptin, alogliptin, vildagliptin, shagliptin, linagliptin, etc.) or glucokinase agonists (doegliptin, etc.)\n* Contraindications to magnetic resonance imaging\n* The risk of complications significantly increases during the perioperative or postoperative period\n* Those with a history of other weight loss surgeries\n* Individuals with a history of cardiovascular surgery and severe cardiovascular and pulmonary diseases: including stroke, severe coronary heart disease, arrhythmia, unstable angina, myocardial infarction within 6 months, peripheral vascular disease, heart failure, and uncontrolled hypertension\n* Clinically significant history of ECG abnormalities or family history of long QT syndrome (grandparents, parents, brothers and sisters)\n* People with a history of kidney disease: have a history or evidence of renal insufficiency, manifested as clinically significant creatinine abnormalities or urinary composition abnormalities (such as tubular abnormalities), or eGFR\\\u003C60 ml\u002Fmin\u002F1.73m2\n* Patients with a history of gastrointestinal surgery (excluding appendectomy and cholecystectomy), inflammatory bowel disease, esophageal disease, including severe refractory esophagitis, Barrett's disease, esophageal motility disorders, or other gastric motility impairments, or those with esophageal hiatal hernia\\>3cm in size, chronic or acute bleeding, including peptic ulcer disease, portal hypertension (gastric or esophageal varices), chronic pancreatitis or cirrhosis\n* Individuals with a history of eating disorders or mental illness\n* Individuals with a history of infectious diseases are excluded if they have any of the following: human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or those who have tested positive for syphilis\n* Smokers, those who smoke more than 10 cigarettes or equivalent amounts of tobacco per day and cannot stop smoking during the trial period\n* There is a history of drug or alcohol abuse within the 12 months prior to the trial, or evidence of such abuse is found during laboratory examinations during the screening period evaluation\n* Women who are pregnant, breastfeeding, or planning to conceive and are unwilling to use contraception during the trial period\n* Malignant tumor patients\n* The researcher believes that it is not suitable for participants in the experiment\n* For different types of subjects, additional exclusion criteria: obese patients with normal glucose tolerance: fasting blood glucose ≥ 7.0 mmol\u002FL or ≤ 3.9 mmol\u002FL (excluding diabetes and hypoglycemia)\n* Obese patients before glucose: fasting blood glucose ≥ 7.0 mmol\u002FL or ≤ 3.9 mmol\u002FL (excluding diabetes and hypoglycemia)\n* Obese T2DM patients: Fasting blood glucose ≤ 3.9 mmol\u002FL (excluding those with hypoglycemia)","ALL","16 Years","65 Years",{"count":19,"type":20},48,"ESTIMATED","OBSERVATIONAL","The study will be conducted in the following population: obese patients with normal glucose tolerance (HbA1c ≤ 5.6%, n=12), pre-sugar patients (5.7% ≤ HbA1c ≤ 6.4%, n=18) and patients with T2DM (HbA1c ≥ 6.4% , n=18). After recruiting, they were followed up at 1, 3, 6, and 12 months postoperatively, and their preoperative and follow-up examination values related to demographics, body composition, blood biochemistry, and glucose metabolic balance, as well as quantitative MRI imaging and oral glucose tolerance test (OGTT) will be collected. An interim analysis will be performed at 6 months postoperatively and overall analysis will be performed at 12 months postoperatively by descriptive statistics and ANOVA methods to explore the effect of adiposity on the progression of diabetes mellitus and insulin secretory function.",[24,25],"Diabete Type 2","Obesity",[24,25],"NOT_YET_RECRUITING","2023-06-07",{"date":30,"type":31},"2023-06-08","ACTUAL",{"date":33,"type":20},"2023-06-01",{"date":35,"type":20},"2026-12-01",{"name":37,"class":38},"Dongyang Liu","OTHER",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":4,"eligibilityCriteria":44,"healthyVolunteers":11,"sex":45,"minAge":46,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":50,"conditions":51,"keywords":54,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":69},"100455231","clinical-pharmacology-of-dexamethasone-in-pregnant-women-with-preterm-labor-100455231","NCT05207852","Clinical Pharmacology of Dexamethasone in Pregnant Women With Preterm Labor","Inclusion Criteria:\n\n* Aged 20-40 (inclusive);\n* Body mass Index (BMI) 18.5-27.9kg \u002Fm2 (inclusive)\n* Single and twin pregnancy;\n* Premature delivery at 24-36 weeks;\n* No antibiotics, prebiotics or probiotics were used one month before feces collection (such as Bifidobacterium triplex live powder, Lactobacillus acidophilus tablet, compound Lactobacillus acidophilus tablet, Bacillus subtilis diplex live intestinal capsule, etc.);\n* Preeclampsia patients accounted for about 1\u002F10 of each group;\n* Use dexamethasone I.M. 5mg Q12h regimen (or other dexamethasone administration regimen) to promote fetal lung maturation.\n\nExclusion Criteria:\n\n* Ectopic pregnancy;\n* Suffering from diabetes, fetal distress, serious infectious diseases (such as sepsis, septic shock), fever;\n* Those who have taken glucocorticoid drugs within 2 weeks before joining the clinical trial;\n* Those who took clindamycin during the study period;\n* Congenital fetal malformation or fetal hypoxia in early pregnancy;\n* Convulsive patients;\n* HIV\u002FHCV\u002F HEPATITIS A, drug abuse history;\n* Suffering from chorioamnitis, endometritis;\n* Placental abruption, severe intrauterine bleeding;\n* Pregnant women whose cervical dilation is greater than or equal to 4 cm or whose cervical length is less than or equal to 20 mm by ultrasound examination;\n* Pregnant women who took food or drugs during the study that might affect the safety of the fetus;\n* Pregnant women participating in other clinical trials.","FEMALE","20 Years","40 Years",{"count":49,"type":20},288,"This study through to the pregnant woman blood concentrations of dexamethasone therapy after research, explore the pharmacokinetic data of dexamethasone in pregnant women, Chinese pregnant women dexamethasone pharmacokinetic model, provide a reference for the clinical use of dexamethasone dose, through the biomarkers of dexamethasone to promote fetal lung maturity and other metabolomics, It provides the basis for the effectiveness and safety study of dexamethasone.",[52,53],"Respiratory Distress Syndrome of Newborn","Threatened Premature Labor, Antepartum",[55,56,57,58,59],"Dexamethasone","Pregnancy","Preterm","Quantitative pharmacology","P-glycoprotein","RECRUITING","2022-01-24",{"date":63,"type":31},"2022-01-26",{"date":65,"type":31},"2021-12-01",{"date":67,"type":20},"2027-12-31",{"name":37,"class":38},1,""]